Helen E. Heslop, MD • SITC 2020 35th Anniversary Keynote

SITC 2020 35th Anniversary Keynote Speaker

Heslop_Photo_KeynoteDan L. Duncan Chair, Professor of Medicine and Pediatrics
Director, Center for Cell and ene Therapy
Houston Methodist Hospital
Texas Children's Hospital, Houston 
Baylor College of Medicine 


35th Anniversary Keynote Address
T cell Therapy of Cancer 


Helen Heslop is Professor of Medicine and Pediatrics at Baylor College of Medicine, and the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. She is also Associate Director for Clinical Research at the Dan L. Duncan Cancer Comprehensive Center. Dr Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. An additional focus in reconstituting antiviral immunity post transplant and she has led an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She therefore has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently holds over 20 INDs. She was a Doris Duke distinguished clinical research scientist and is an elected member of the American Association of Physicians. She serves as Principal Investigator on several peer-reviewed research programs, including an NCI-funded program project grant (Enhancing T-Cell Therapy of Cancer) a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) award (Immunotherapy of Lymphoma), the Meg Vosberg Stand Up to Cancer Dream Team in T cell lymphoma and a SPORE in lymphoma from the NCI. She is also the principal investigator on an NHLBI-funded training grant in Cell and Gene Therapy and Chair-elect of the BMT-CTN. She is a past President of the American Society for Gene and Cell Therapy (ASGCT), the American Society of Blood and Marrow Transplant (ASBMT) and the Foundation for Accreditation of Cell Therapy (FACT).